Intercept +5.6% AH on FDA fast-track designation


The FDA has granted fast-track designation for the use of obethicholic acid (OCA) for treating primary biliary cirrhosis (PBC).

Intercept (ICPT) plans to complete a new drug application for OCA in 1H15. The NDA will include data from Intercept's Phase 3 trial and two randomized Phase 2 trials.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs